Researchers Call for Expansion of Mint Tobacco Ban

Dec.08.2022
Researchers Call for Expansion of Mint Tobacco Ban
Researchers urge FDA to expand ban on mint-flavored tobacco products to include potential substitutes like mint pipes and cigarillos.

Researchers from the Rutgers Tobacco Research Center and Ohio State University are calling for the US Food and Drug Administration (FDA) to expand the ban on mint-flavored cigarettes and cigars to include potential alternatives like mint-flavored pipes and rolling papers.


According to a study published in the journal Tobacco Control, researchers are urging the FDA to maximize the benefits of the ban on menthol-flavored cigarettes based on new evidence showing that these alternatives are attractive and have the potential to be addictive for adults who smoke menthol cigarettes.


Andrea Villanti, Associate Director of the Rutgers University Tobacco Research Center, stated that tobacco companies have renamed their roll-your-own tobacco as pipe tobacco to avoid taxes, and have branded flavored cigarettes as flavored cigars to evade federal bans. Villanti, the lead researcher of the study, said, "We have seen companies promoting pipe tobacco and cigarillos alongside cigarettes and filtered cigars. The products we tested in our research are likely the ones tobacco companies will promote after mint-flavored cigarettes are banned.


Researchers examined 98 adults who smoked menthol cigarettes to compare the addictive potential of combustible menthol with its substitutes. The study was conducted in four parts over a three-week period, during which participants first smoked their usual brand of menthol cigarettes. In the next three sessions, participants were randomly assigned three different menthol cigarette substitutes:


One cigarette that does not contain menthol alcohol is a pre-assembled menthol cigarette made with mint tobacco and a menthol pipe for filtering. It also includes a small menthol cigar.


During each meeting, researchers measured the smoking habits of participants, including the amount of carbon monoxide emitted, cravings, and withdrawal symptoms. Participants also self-reported their perceived effects of the drug and evaluated other measures of addiction potential for each product.


The team discovered that while menthol-filtered small cigars and non-mentholated cigarettes are attractive alternatives to menthol cigarettes, menthol pipe tobacco and rolling papers are the most alluring and lead to the highest number of indicators for future nicotine addiction. However, these products have not been considered for inclusion in the proposed ban.


According to the investigation results, the components of menthol cigarette products, including menthol paper, cigarette tube, and tobacco for pipe, should be included in the standards for menthol cigarettes and flavored cigars, as stated by Villanti.


Previous research has established a correlation between the use of menthol-flavored cigarettes and an increase in smoking initiation, nicotine dependence, and reduced adult smoking cessation, particularly among vulnerable populations. The FDA has proposed a regulation prohibiting the use of menthol as a flavoring agent in cigarettes and cigars to address this public health concern. Following a review of public feedback, a final decision is expected to be made in the coming months.


Currently, research results indicate that the components of menthol cigarette products, including menthol cigarette paper, filters, and tobacco, should be included in the standards for menthol cigarettes and flavored cigars," said Theodore Wagener, director of the center. The research was conducted by the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and the lead author of the study. "Failing to comply with this restriction would result in a serious loophole that the tobacco industry has already exploited and could potentially weaken the potential public health benefits of the proposed menthol ban.


2FIRSTS will continue to provide ongoing coverage of this topic, with further updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Major U.S.  Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
Major U.S. Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
New York vape distributor Ecto World, which operates as Demand Vape, hired political consultant Roger Stone to lobby the Executive Office of the President on regulation of vaping and related products while facing state enforcement and multiple lawsuits. Public lobbying disclosures show that Ecto World paid at least $300,000 for the work through June 30, 2026. Separately, New York State announced in March that more than 28,500 pounds of vaping products tied to the company had been seized, while New York City and the state have pursued legal or enforcement actions. Public records do not show that the lobbying directly changed any specific regulatory or enforcement outcome.
Sep.08
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin Vape Directory One Year On: Retailer Reports Four Store Closures and 70% Staff Cuts
Wisconsin's electronic vaping device directory has been fully enforced for more than a year, and local vape retailers say the reduced range of eligible products has contributed to declining sales, store closures and layoffs. Johnny Vapes owner Ben Hall said he has closed four of seven locations and cut about 70% of his staff. State law bars the sale of vaping devices not listed on the Wisconsin Department of Revenue directory and allows penalties of $1,000 per day for each unlisted device sold or offered for sale. In April 2026, the U.S. Court of Appeals for the Seventh Circuit allowed enforcement of the law to continue.
Regulations
Oct.10
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07